Key result
Simvastatin inhibits mesangial JAK/STAT signaling and reduces albumin excretion in diabetic models.
Answers are grounded in this paper and cite their sources.
In the current study, we investigated the effect of simvastatin on the ability of high glucose (HG) and ANG II to activate the JAK2-STAT signaling cascade and induce glomerular mesangial cell (GMC) growth. We found that pretreatment with simvastatin significantly inhibited HG- and ANG II-induced collagen IV production, JAK2 activation, and phosphorylation of STAT1 and STAT3 in GMC. We also found that the activation of JAK2 by HG and ANG II was dependent on the Rho family of GTPases. Consistent with these in vitro results, both albumin protein excretion and phosphorylation of JAK2, STAT1, and STAT3 were attenuated in renal glomeruli by administration of simvastatin in a streptozotocin-induced rat model of HG diabetes. This study demonstrates that simvastatin blocks ANG II-induced activation of the JAK/STAT pathway in the diabetic environment, in vitro and in vivo, and, thereby, provides new insights into the molecular mechanisms underlying early diabetic nephropathy.
No takes yet. Share an insight, caveat, or question.
Banes‐Berceli et al. (2006) studied Diabetic nephropathy. Simvastatin vs. Control was evaluated on Activation of JAK2-STAT signaling cascade, collagen IV production, and albumin protein excretion. Simvastatin significantly inhibited high glucose- and angiotensin II-induced activation of the JAK/STAT pathway in mesangial cells and attenuated albumin excretion in a diabetic rat model.
Synapse has enriched 10 related papers. Consider them for comparative context: